Details for New Drug Application (NDA): 205609
✉ Email this page to a colleague
NDA 205609 describes ETHACRYNIC ACID, which is a drug marketed by Adaptis, Agnitio, Alvogen, Amneal Pharms Co, Chartwell Rx, Endo Operations, Hikma, Lupin Ltd, Sciegen Pharms Inc, and Upsher Smith Labs, and is included in ten NDAs. It is available from eight suppliers. Additional details are available on the ETHACRYNIC ACID profile page.
The generic ingredient in ETHACRYNIC ACID is ethacrynic acid. There are thirteen drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the ethacrynic acid profile page.
The generic ingredient in ETHACRYNIC ACID is ethacrynic acid. There are thirteen drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the ethacrynic acid profile page.
Summary for 205609
| Tradename: | ETHACRYNIC ACID |
| Applicant: | Adaptis |
| Ingredient: | ethacrynic acid |
| Patents: | 0 |
Pharmacology for NDA: 205609
| Physiological Effect | Increased Diuresis at Loop of Henle |
Medical Subject Heading (MeSH) Categories for 205609
Suppliers and Packaging for NDA: 205609
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| ETHACRYNIC ACID | ethacrynic acid | TABLET;ORAL | 205609 | ANDA | Edenbridge Pharmaceuticals LLC. | 42799-405 | 42799-405-01 | 100 TABLET in 1 BOTTLE (42799-405-01) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 25MG | ||||
| Approval Date: | Jun 30, 2016 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
